Helicobacter pylori plays major causative roles in peptic ulcer disease and gastric cancer. Elevated acid secretion in patients with duodenal ulcers (DUs) contributes to duodenal injury, and diminished acid secretion in patients with gastric cancer allows carcinogen-producing bacteria to colonize the stomach. Eradication of H. pylori normalizes acid secretion both in hyper-secreting DU patients and hypo-secreting relatives of gastric cancer patients. Therefore, we and others have asked how H. pylori causes these disparate changes in acid secretion.
INTRODUCTION
Gastric acid secretion plays an important role in gastro-esophageal reflux disease (GERD)b. It recently became clear that Helicobacterpylori is an important etiological factor in other upper gastrointestinal diseases including gastric and duodenal ulcers and gastric cancer, and there is evidence that changes in gastric acid secretion caused by the bacterium contribute to the pathogenesis of these diseases. This article will examine the aTo whom all correspondence should be addressed: Professor John Calam, M.D., FR.C.R, caIam~@rpms.ac.uk Abbreviations: GERD, gastro-esophageal reflux disease; DU, duodenal ulcer; ECL, enterochromaffin like; TNFa, tumor necrosis factor alpha; GRP, gastrin releasing peptide; MAO, maximal acid output. 195 evidence, and whether effects of H. pylori on gastric physiology are relevant to GERD. First I will consider the effect of H. pylori on the endocrine and exocrine cells of the stomach, then consider how and why how H. pylori affects acid secretion in differently in different disease groups. Finally I will ask whether H. pylori's effects on acid secretion are relevant to the pathogenesis and treatment of GERD.
EFFECTS OF H. PYLORI ON GAS-TRIC CELLS (SEE FIGURE 1)
G-cells Gastrins are realized from G-cells in the gastric antrum and proximal duodenum. They act via the circulation to stimulate acid secretion, both by stimulating parietal cells directly and by releasing histamine from nearby enterochromaffin-like (ECL)-cells. H. pylori infection elevates plasma gastrin concentrations under all conditions studied so far [1] .
Products of H. pylori itself, or inflammatory factors from the host might be responsible. H. pylori's enzyme urease produces copious ammonia, and diets supplemented with ammonium acetate elevated circulating gastrin in rats. However, the salt also causes gastritis, which might have contributed. However, a urease inhibitor failed to decrease plasma gastrin levels, so other H. pylori products might be responsible. The bacterium is reported to produce N-a-methylhistamine which we find to release gastrin from G-cells via histamine H2 receptors [1, 2] [1] . This lack of somatostatin may explain increases in gastrin release and acid secretion in infected subjects.
It is difficult to measure responses of gastric D-cells in vivo, but we found that a three-hour infusion of gastrin-releasing peptide significantly elevates the somatostatin content of antral biopsies, showing that the cells are capable of responding, but the amount remained well below that present in uninfected persons [5] . The mechanism responsible for diminished somatostatin remains unclear but we found that incubation of D-cells with TNFa for 24 hours diminished somatostatin release [6] . [8] . Therefore N-amethyl histamine produced by H. pylori [1] Effects of H. pylori on inhibitory control of acid secretion H. pylori infection causes defects in the reflex inhibition of acid secretion that were previously observed in patients with duodenal ulcer (DU) disease and are attributable to the paucity of mucosal somatostatin.
ECL-cells
Basal acid secretion. Eradication of H. pylori produces a significant fall in basal acid secretion in DU patients [11, 12] , but this has not generally been found in non-ulcer patients. Perhaps acid secretion in DU patients, who have less corpus gastritis, reflects changes in hormonal influences, while in non-ulcer patients an improvement in corpus gastritis after eradication causes a confounding increase in acid.
Meal-stimulated acid secretion at a low intragastric pH. H. pylori impairs inhibition of peptone-stimulated acid secretion by a low intragastric pH. The low pH suppressed acid secretion by greater than 80 percent in uninfected persons but by less than 50 percent in infected volunteers [13] . Acid secretion stimulated by neutral peptone was similar in both groups, indicating that the abnormality lies in the inhibitory pathway.
The inhibitory effect of antral distension. Antral distension normally inhibits pentagastrin-stimulated acid secretion, but this reflex is also attenuated by H. pylori infection [1] .
The inhibitory effect of cholecystokinin infusion. It was recently found that CCK infusions inhibit GRP-stimulated acid secretion less in H. pylori infected persons [1] . This is consistent with a lack of cholecystokinin-stimulated somatostatin release.
Gastrin [14] . Therefore, the raised MAO in DU patients seems to be a response to H. pylori infec-tion, which might be mediated by the trophic effect of gastrin, or some other growth factor on the corpus mucosa.
Low acid secretion on first infection and in patients with gastric cancer. In contrast, acid secretion more or less disappears for the first few weeks or months of H. pylori infection [15] , and is markedly diminished in patients who develop gastric cancer [16] . Interestingly about half of the first-degree relatives of patients with gastric cancer have diminished acid secretion, which rises when the infection is eradicated [17] [18] , so gastro-esophageal reflux disease (GERD) is regarded as a disorder of motility rather than secretion. However, the effect of H. pylori infection on responses to proton pump inhibitors [19] , which are the main medical treatment for esophagitis, may be clinically important, and provides an important insight into the relationship between the bacterium and altered gastric physiology.
WHY DO DIFFERENT Parietal cell mass. In the past, an individual's parietal cell mass and MAO were regarded as closely related and more-orless fixed. It was appreciated that gastric atrophy produces a parallel fall in both as parietal cells are lost. However, it is now appreciated that parietal cells remain but fail to secrete acid on first infection [15] , and that bacterial products and cytokines decrease the maximal secretory capacity of parietal cells in vitro [20] .
Distribution of gastritis ( Figure 2 ). There is a two-way relationship between distribution of gastritis and acid output. The antral predominant gastritis found in DU patients is associated with hypersecretion, while the pangastritis is found in patients with gastric cancer who secrete little acid. One direction is that the distribution of gastritis determines acid output, depending on whether corpus mucosa is healthy enough to respond to gastrin. However, the effect of suppressing acid with omeprazole suggests that the reverse also occurs. Omeprazole decreases gastritis and colonization in the antrum while in the corpus, gastritis increases and colonization increases or stays the same [21] .
Therefore, it is possible to envisage a vicious circle whereby hyposecretion and corpus gastritis become self-perpetuating.
Gastric atrophy. H. pylori infection promotes the development of atrophy [10] , and suppression of acid secretion with proton pump inhibitors may accelerate this process [22] [22] . However, the validity of this finding and its clinical relevance remain highly controversial. 2) H. pylori infection significantly increases the pH-elevating effect of proton pump inhibitors [19] . This may be due to generation of alkali by the bacterium's urease or an increase in corpus gastritis. We find that both H. pylori sonicates and IL-1i[ add to the antisecretory effect of omeprazole on parietal cells in vitro [24] . 3) German studies suggest that eradicating H. pylori from DU patients increases the likelihood of GERD subsequently appearing [25] . The initial severity of corpus gastritis predicted the likelihood of GERD, so an elevation of acid secretion following cure might have contributed. However weight gain was also implicated, and it remains unclear whether the main observation is reproducible.
Points 2) and 3) argue against eradicating H. pylori from patients with GERD, and clinical studies largely show no improvement in symptoms when this is done. However the possibility, however remote, that proton pump inhibitor therapy exacerbates H. pylori gastritis persuades most clinicians to eradicate before longterm therapy.
CONCLUSION
In summary, therefore, there is currently no evidence that H. pylori-related changes in acid secretion contribute to the pathogenesis of GERD, although the data on the topic are distinctly scanty. Further research is required to clarify whether H. pylori should be eradicated prior to longterm administration of proton pump inhibitors to patients with GERD. This is likely to render therapy less effective, but might protect the stomach from developing atrophy, although this remains highly controversial.
